A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.

Vered Stearns(Johns Hopkins University), Daniel F. Hayes(University of Michigan–Ann Arbor), Rebecca Slack, Cecilia Tibery, Theodore N. Tsangaris(Georgetown University), Antonella Novielli, Baljit Singh(Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences), Claudine Isaacs(Georgetown University), Mathew J. Ellis, J. Crawford, A.-S. Farhad, Marie Pennanen(Unknown)
PubMed
January 1, 2003
Cited by 109

Related Papers

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k